9.94 +0.23 (2.35%)
ISIS
Stock Details
Last Trade:9.94 Change:+0.23 (2.35%) Prev Close:9.71 Open: 9.78 Days Range:9.70 – 9.95 52 Week Range: 8.59 - 18.81 Volume:2501528 P/E: N/AEPS:-0.31
View AllRecent Alerts 03/20/10
Recent Alert on 03/15/10 at 9:13am
Genzyme (GENZ) and Isis Pharma (ISIS) Mipomersen Phase 3 Meets Primary Endpoint
Genzyme (GENZ) and Isis Pharma (ISIS) Mipomersen Phase 3 Meets Primary Endpoint
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its... Read More
Recent Alert on 03/15/10 at 9:13am
Genzyme (GENZ) and Isis Pharma (ISIS) Mipomersen Phase 3 Meets Primary Endpoint
Genzyme (GENZ) and Isis Pharma (ISIS) Mipomersen Phase 3 Meets Primary Endpoint
Recent Alert on 03/10/10 at 8:53am
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
Recent Alert on 03/10/10 at 8:53am
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
Recent Alert on 03/08/10 at 7:11am
Isis Pharma (ISIS) Earns $6M Milestone Payment from Bristol-Myers Squib (BMY)
Isis Pharma (ISIS) Earns $6M Milestone Payment from Bristol-Myers Squib (BMY)
View AllRecent Press Releases
Press Release on 03/17/10 at 8:00am
Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
Press Release on 03/17/10 at 7:00am
Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
View AllRecent SEC Filings
No Recent SEC Filings Available